NFCR Press Release NFCR Writer David Perry July 21, 2018 In both mouse and culture-dish experiments, researchers at the Dana-Farber/Boston Children’s Cancer and Blood Disorders Center found that a new line of drugs called CDK inhibitors may herald a new age in treatment for Ewing sarcoma, a cancer in children and adolescents affecting the bones and soft tissue surrounding the bones. “No one has previously considered CDK12 inhibition as a way to combat Ewing sarcoma,” says Kimberly Stegmaier, M.D., senior author of the new Cancer Cell paper describing the findings. She refers to one of a series of proteins known…
Browsing: NEWS
1) Findings: Insights and developments globally on the subject.
2) Companies: Updates and progress reports on member companies.
3) Industry: Important developments from throughout the field.
Soligenix, Inc. (Nasdaq: SNGX), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, recently announced that its President and Chief Executive Officer, Christopher J. Schaber, PhD, is to deliver a corporate presentation at the 2017 Biotech & Money Inv€$tival Showcase in London, England on Tuesday, November 14 at 1:30 PM GMT. The event will take place at The Waldorf Hilton Hotel. Biotech and Money connects corporates to capital, and the Inv€$tival Showcase is the most direct way of showcasing the latest investable private and public life science opportunities…
Soligenix’s self-described “DOM–INNATE” study has initiated patient enrollment. The late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced that patient enrollment has been opened for its Phase 3, multinational, randomized, double-blind, placebo-controlled study evaluating SGX942 (dusquetide) as a treatment for severe oral mucositis in patients with head and neck cancer receiving chemoradiation therapy (CRT). Mucositis is the clinical term for damage done to the mucosa by anticancer therapies. It can occur in any mucosal region, but is most commonly associated with the mouth, followed by the small intestine.…
Now in its 19th year, the BIO CEO & Investor Conference is one of the largest investor conferences focused on established and emerging publicly traded and select private biotech companies. With a mission to support industry-wide success, the conference offers a broad and unbiased view of investment opportunities. BIO CEO sets itself apart by providing a neutral forum where institutional investors, industry analysts, and senior biotechnology executives have the opportunity to shape the future investment landscape of the biotechnology industry. This year’s conference was no exception, as it featured issue-oriented and educational sessions focused on trending therapeutic areas and key business issues, company presentations, one-on-one meetings,…
As Senior Vice President of Strategic Initiatives at the New York Stem Cell Foundation, Stephen Chang is one of the leading experts in gene therapy and neurodegenerative. Dr. Chang speaks with Brett Johnson on the state of the industry, explains what we can expect from the field in the future and offers his advice for investors and entrepreneurs who are active in the space. Brett Johnson: Can you give an update as to what’s happened since we spoke last at the New York Stem Cell Foundation? Any developments? Stephen Chang: It is exciting times. We are moving into a new…
Bioinformatics is the field of science involved with using computational methods to convert raw biological data into meaningful biological paradigms. Part I of this article will discuss how bioinformatics data is generated. It will focus on the methods used to collect this data, and the companies that support this collection.
Actium Cancer Treatment (ACT) platform’s controlled heat (hyperthermia) has the potential to substantially increase the efficacy of chemotherapy and radiation First application: non-muscle-invasive bladder cancer (NMIBC).
Atossa Genetics believes it can prevent breast cancer by 2020 — and in the meantime, capture a unique market opportunity — with their novel cellular and molecular diagnostic risk assessment products for early detection. Yet in a burgeoning diagnostics space, and rapid advancement in cancer therapeutics, will this company find a niche?